인쇄하기
취소

Obesity therapy Saxenda lands in 10 general hospitals including Seoul National University Hospital

Published: 2018-05-24 10:59:51
Updated: 2018-05-24 10:59:51

Novo Nordisk Korea(CEO Rana Azfar Zafar) announced on the 21st that ‘Saxenda® (generic name: liraglutide 3.0mg),’ the world’s first and only GLP-1(Glucagon-Like Peptide 1) analogue for the treatment of obesity, will be extensively landing into 10 general hospitals including Seoul National University Hospital.

Launched for the first time in Asia last March, Saxenda landed in total 10 general ho...

Fees

- Email service daily and homepage access.
  1. $300 per month.
  2. 5 Email holders per each company.
  3. Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.